SCHEDULE 14A INFORMATION
PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE
SECURITIES EXCHANGE ACT OF 1934
(AMENDMENT NO. )
Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐
Check the appropriate box:
☒ | Preliminary Proxy Statement | |
☐ | Definitive Proxy Statement | |
☐ | Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) | |
☐ | Definitive Additional Materials | |
☐ | Soliciting Material Pursuant to §240.14a-12 |
HERBALIFE NUTRITION LTD.
(Name of Registrant as Specified In Its Charter)
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check the appropriate box):
☒ | Fee not required. | |||
☐ | Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11. | |||
(1) | Title of each class of securities to which transaction applies:
| |||
(2) | Aggregate number of securities to which transaction applies:
| |||
(3) | Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
| |||
(4) | Proposed maximum aggregate value of transaction:
| |||
(5) | Total fee paid:
| |||
☐ | Fee paid previously with preliminary materials. | |||
☐ | Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing. | |||
(1) | Amount Previously Paid:
| |||
(2) | Form, Schedule or Registration Statement No.:
| |||
(3) | Filing Party:
| |||
(4) | Date Filed:
|
PRELIMINARY PROXY STATEMENT
SUBJECT TO COMPLETION
DATED MARCH 5, 2020
Herbalife Nutrition Ltd.
2020 Proxy Statement
|
Annual General Meeting of Shareholders
Our 2020 Annual General Meeting of Shareholders
will be held on Wednesday, April 29, 2020 at 8:30 a.m., Pacific Daylight Time, at:
800 W. Olympic Blvd., Suite 406
Los Angeles, CA 90015
Admission requirements
See Part 1 Information concerning solicitation and voting for details on admission requirements to attend the Annual General Meeting.
Herbalife Nutrition Ltd.
Notice of Annual General Meeting of Shareholders
Date: | Wednesday, April 29, 2020 | |
Time: | 8:30 a.m., Pacific Daylight Time | |
Place: | 800 W. Olympic Blvd., Suite 406 Los Angeles, CA 90015 | |
Record date: | March 2, 2020 | |
Proxy voting: | All shareholders are cordially invited to attend the Annual General Meeting in person. See Part 1 Information concerning solicitation and voting for details on admission requirements to attend the Annual General Meeting.
However, to assure your representation at the Annual General Meeting, you are urged to vote promptly. You may vote your shares via a toll-free telephone number, over the Internet or by completing, signing and mailing the proxy card or voting instruction form provided to you. Please follow the instructions on the proxy card or voting instruction form provided to you. | |
Items of business: | 1. Elect the 13 directors named in the Proxy Statement to the Board of Directors to serve until the 2021 annual general meeting of shareholders of the Company or until their successors are duly elected and qualified;
2. Approve, on an advisory basis, the compensation of the Companys named executive officers;
3. Approve, as a special resolution, an amendment to the Companys Amended and Restated Memorandum and Articles of Association (the Articles) to eliminate the casting vote;
4. Approve, as a special resolution, an amendment to the Articles to require the approval of two-thirds of the members of the Board of Directors then in office to amend the Companys Principles of Corporate Governance to make any changes to the responsibilities of the Chairman of the Board or the Lead Director as set forth therein; and
5. Ratify the appointment of the Companys independent registered public accounting firm for fiscal year 2020.
Shareholders will also act upon such other matters as may properly come before the Annual General Meeting. | |
The foregoing items of business are more fully described in the Proxy Statement accompanying this Notice. Only shareholders of record at the close of business on March 2, 2020 are entitled to notice of, and to vote at, the Annual General Meeting and any subsequent adjournment(s) or postponement(s) thereof. | ||
Availability of Materials: |
The Proxy Statement and Annual Report to Shareholders are available at http://www.envisionreports.com/HLF. |
NOTICE IS HEREBY GIVEN that the 2020 Annual General Meeting of Shareholders of Herbalife Nutrition Ltd., a Cayman Islands exempted company incorporated with limited liability, or the Company, will be held on Wednesday, April 29, 2020 at 8:30 a.m., Pacific Daylight Time, at 800 W. Olympic Blvd., Suite 406, Los Angeles, CA 90015.
Sincerely,
HENRY C. WANG
General Counsel and Corporate Secretary
Los Angeles, California
March , 2020
Proxy summary
This summary highlights information contained elsewhere in this Proxy Statement. You should carefully read this Proxy Statement in its entirety prior to voting on the proposals listed below and outlined herein. This Proxy Statement is dated March , 2020 and is first being made available to shareholders of Herbalife Nutrition Ltd., a Cayman Islands exempted company incorporated with limited liability, or the Company, on or about March , 2020. A Notice Regarding Internet Availability of Proxy Materials for the 2020 Annual General Meeting of Shareholders, or the Meeting, was mailed to shareholders of the Company on or about March , 2020.
Annual General Meeting of Shareholders
Date: | Wednesday, April 29, 2020 | |
Time: | 8:30 a.m., Pacific Daylight Time | |
Place: | 800 W. Olympic Blvd., Suite 406 Los Angeles, CA 90015 | |
Record date: | March 2, 2020 | |
Voting: | Shareholders as of the record date are entitled to vote. |
Admission to Meeting: Proof of share ownership will be required to enter the Meeting. See Part 1 Information concerning solicitation and voting for details on admission requirements to enter the Meeting.
Meeting agenda
1. | Elect the 13 directors named in the Proxy Statement to the Board of Directors to serve until the 2021 annual general meeting of shareholders of the Company or until their successors are duly elected and qualified; |
2. | Approve, on an advisory basis, the compensation of the Companys named executive officers; |
3. | Approve, as a special resolution, an amendment to the Companys Amended and Restated Memorandum and Articles of Association (the Articles) to eliminate the casting vote; |
4. | Approve, as a special resolution, an amendment to the Articles to require the approval of two-thirds of the members of the Board of Directors then in office to amend the Companys Principles of Corporate Governance to make any changes to the responsibilities of the Chairman of the Board or the Lead Director as set forth therein; and |
5. | Ratify the appointment of the Companys independent registered public accounting firm for fiscal year 2020. |
Shareholders will also act upon such other matters as may properly come before the Meeting.
Proxy summary |
ii | Table of Contents |
Proposal |
Voting Options | Board
|
Vote Required
|
Effect of
|
Effect of
| |||||
Item 1: Elect the 13 directors named in the Proxy Statement to the Board of Directors to serve until the 2021 annual general meeting of shareholders of the Company or until their successors are duly elected and qualified |
For, Against or Abstain on each nominee | FOR each nominee | Majority of votes cast FOR with respect to each such nominee |
No effect |
No effect | |||||
Item 2: Approve, on an advisory basis, the compensation of the Companys named executive officers |
For, Against or Abstain | FOR | Majority of shares represented in person or by proxy and entitled to vote |
Treated as votes Against |
No effect | |||||
Item 3: Approve, as a special resolution, an amendment to the Companys Amended and Restated Memorandum and Articles of Association to eliminate the casting vote |
For, Against or Abstain | FOR | 66.67% of the shares represented in person or by proxy and entitled to vote |
Treated as votes Against |
No effect | |||||
Item 4: Approve, as a special resolution, an amendment to the Companys Amended and Restated Memorandum and Articles of Association to require the approval of two-thirds of the members of the Board of Directors then in office to amend the Companys Principles of Corporate Governance to make any changes to the responsibilities of the Chairman of the Board or the Lead Director as set forth therein |
For, Against or Abstain | FOR | 66.67% of the shares represented in person or by proxy and entitled to vote |
Treated as votes Against |
No effect | |||||
Item 5: Ratify the appointment of Companys independent registered public accounting firm for fiscal year 2020 |
For, Against or Abstain | FOR | Majority of shares represented in person or proxy and entitled to vote |
Treated as votes Against |
Brokers have discretion to vote |
YOUR VOTE IS VERY IMPORTANT. Whether or not you plan to attend the Meeting, please take the time to vote. You may vote your shares via a toll-free telephone number, over the Internet or by completing, signing and mailing the proxy card or voting instruction form provided to you. Please follow the instructions on the proxy card or voting instruction form.
2 | Our annual general meeting of shareholders |
Important Notice Regarding the Availability of Proxy Materials for the Annual General Meeting of Shareholders to Be Held on April 29, 2020. The Proxy Statement and Annual Report to Shareholders are available at http://www.envisionreports.com/HLF.
Our annual general meeting of shareholders | 3 |
Corporate governance | 7 |
8 | Corporate governance |
The table below summarizes the compensation paid by the Company to non-management directors for the fiscal year ended December 31, 2019.
Name |
Fees earned or paid in cash ($)
|
Equity awards ($)(1) |
All other compensation
|
Total ($) |
||||||||||||
Dr. Richard Carmona
|
|
110,000
|
|
|
134,988
|
|
|
50,000
|
(3)
|
|
294,988
|
| ||||
Jonathan Christodoro
|
|
120,000
|
|
|
134,988
|
|
|
|
|
|
254,988
|
| ||||
Jeffrey T. Dunn(2)
|
|
80,600
|
|
|
159,987
|
|
|
|
|
|
240,587
|
| ||||
Hunter C. Gary
|
|
110,000
|
|
|
134,988
|
|
|
|
|
|
244,988
|
| ||||
Nicholas Graziano
|
|
110,000
|
|
|
134,988
|
|
|
|
|
|
244,988
|
| ||||
Alan LeFevre
|
|
130,000
|
|
|
134,988
|
|
|
|
|
|
264,988
|
| ||||
Jesse A. Lynn
|
|
120,000
|
|
|
134,988
|
|
|
|
|
|
254,988
|
| ||||
Juan Miguel Mendoza
|
|
100,000
|
|
|
134,988
|
|
|
1,299,045
|
(4)
|
|
1,534,033
|
| ||||
Michael Montelongo
|
|
129,400
|
|
|
134,988
|
|
|
|
|
|
264,388
|
| ||||
James L. Nelson
|
|
151,000
|
|
|
159,950
|
|
|
|
|
|
310,950
|
| ||||
Maria Otero
|
|
135,000
|
|
|
134,988
|
|
|
|
|
|
269,988
|
| ||||
Margarita Paláu-Hernández
|
|
109,000
|
|
|
134,988
|
|
|
|
|
|
243,988
|
| ||||
John Tartol
|
|
100,000
|
|
|
134,988
|
|
|
1,424,790
|
(5)
|
|
1,659,778
|
|
(1) | Amounts represent the aggregate grant date fair value of the relevant award(s) presented in accordance with ASC Topic 718, CompensationStock Compensation. See note 9 of the notes to consolidated financial statements included in the Companys Annual Report on Form 10-K for the year ended December 31, 2019 regarding assumptions underlying the valuation of equity awards. |
(2) | Mr. Dunn resigned from the Board effective July 22, 2019. |
(3) | Amount represents fees for speaking at Herbalife Nutrition events. |
(4) | Amount includes $90,000 in fees for speaking at Herbalife Nutrition events for Herbalife Nutrition Members. Additionally, unrelated to his service as a board member, amount also includes $1,209,045 in income earned as a top distributor of Herbalife Nutrition products. All Herbalife Nutrition Members, including Mr. Mendoza, are eligible to receive income under the Companys Marketing Plan as a result of their activities as distributors of Herbalife Nutrition products. |
(5) | Amount includes $22,500 in fees for speaking at Herbalife Nutrition events for Herbalife Nutrition Members. Additionally, unrelated to his service as a board member, amount also includes $1,402,290 in income earned as a top distributor of Herbalife Nutrition products. All Herbalife Nutrition Members, including Mr. Tartol, are eligible to receive income under the Companys Marketing Plan as a result of their activities as distributors of Herbalife Nutrition products. |
Each non-management director receives annual fees for service on the Board and Committees as follows:
Board service |
$100,000 per year | |
Audit Committee service |
Member - $10,000 per year Chair - $20,000 per year | |
Compensation Committee service |
Member - $10,000 per year Chair - $15,000 per year | |
Nominating and Corporate Governance Committee service |
Member - $10,000 per year Chair - $15,000 per year | |
Implementation Oversight Committee service |
Member $10,000 per year Chair - $20,000 per year |
* | Chairpersons receive chair fees in addition to member fees. For example, the chair of the audit committee receives an aggregate fee of $30,000 for his services on the committee. |
The Lead Director receives an annual fee of $25,000 per year for additional services provided in that capacity.
Corporate governance | 9 |
The table below summarizes the equity-based awards held by non-management directors who served on the Companys Board of Directors in 2019, as of December 31, 2019.
Name | Options/Stock Appreciation Rights |
Stock Unit Awards |
||||||||||||||||||||||
Number of securities underlying unexercised options/SARs (#) exercisable |
Number of securities underlying unexercised options/SARs (#) unexercisable |
Exercise price ($) |
Expiration date |
Number of Shares or units of stock that have not vested (#) |
Market value of Shares or units of stock that have not vested(1) ($) |
|||||||||||||||||||
Dr. Richard Carmona |
|
9,052 |
|
|
|
|
|
39.79 |
|
|
12/19/2020 |
|
|
|
|
|
|
| ||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,689 |
|
|
128,185 |
| ||||||
Jonathan Christodoro |
|
9,052 |
|
|
|
|
|
39.79 |
|
|
12/19/2020 |
|
|
|
|
|
|
| ||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,689 |
|
|
128,185 |
| ||||||
Jeffrey T. Dunn(2) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Hunter C. Gary |
|
|
|
|
|
|
|
|
|
|
|
|
|
2,689 |
|
|
128,185 |
| ||||||
Nicholas Graziano |
|
|
|
|
|
|
|
|
|
|
|
|
|
2,689 |
|
|
128,185 |
| ||||||
Alan LeFevre |
|
|
|
|
|
|
|
|
|
|
|
|
|
2,689 |
|
|
128,185 |
| ||||||
Jesse Lynn |
|
|
|
|
|
|
|
|
|
|
|
|
|
2,689 |
|
|
128,185 |
| ||||||
Juan Miguel Mendoza |
|
|
|
|
|
|
|
|
|
|
|
|
|
2,689 |
|
|
128,185 |
| ||||||
Michael Montelongo |
|
|
|
|
|
|
|
|
|
|
|
|
|
2,689 |
|
|
128,185 |
| ||||||
James L. Nelson |
|
|
|
|
|
|
|
|
|
|
|
|
|
2,689 |
|
|
128,185 |
| ||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
655 |
|
|
31,224 |
| ||||||
Maria Otero |
|
9,052 |
|
|
|
|
|
39.79 |
|
|
12/19/2020 |
|
|
|
|
|
|
| ||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,689 |
|
|
128,185 |
| ||||||
Margarita Paláu-Hernández |
|
|
|
|
|
|
|
|
|
|
|
|
|
2,689 |
|
|
128,185 |
| ||||||
John Tartol |
|
9,052 |
|
|
|
|
|
39.79 |
|
|
12/19/2020 |
|
|
|
|
|
|
| ||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,689
|
|
|
128,185
|
|
(1) | Market value based on the closing price of a Common Share on the NYSE on December 31, 2019 of $47.67. |
(2) | Former member of the Board. |
10 | Corporate governance |
Current committee memberships
Independent Directors | Audit(1) | Compensation(2) | Implementation Oversight |
Nominating Corporate Governance | ||||
Dr. Richard Carmona |
|
|
|
● | ||||
Jonathan Christodoro |
|
|
● | ● | ||||
Hunter C. Gary |
|
● |
|
| ||||
Nicholas Graziano |
|
● |
|
| ||||
Alan LeFevre * | Chair |
|
|
| ||||
Jesse A. Lynn |
|
|
● | ● | ||||
Michael Montelongo | ● | Chair |
|
| ||||
James L. Nelson | ● |
|
Chair |
| ||||
Maria Otero |
|
|
● | Chair | ||||
Margarita Paláu-Hernández |
|
● |
|
|
* Audit Committee financial expert ● Member
(1) | Jeff Dunn served on the Audit Committee until July 22, 2019, and Mr. Montelongo was appointed to the Audit Committee on July 22, 2019. Each member who served on the Committee during 2019 is financially literate and met the independence requirements of the NYSE, the Securities Exchange Act of 1934, as amended (the Exchange Act), and the Companys Principles of Corporate Governance. The Board designated Mr. LeFevre as an Audit Committee financial expert. |
(2) | Jeff Dunn served on the Compensation Committee until February 7, 2019, and Ms. Paláu-Hernández was appointed to the Compensation Committee on February 7, 2019. Each member of the Compensation Committee is (a) independent under the listing standards of the NYSE and the Companys independence standards and (b) a nonemployee director under Rule 16b-3 of the Exchange Act. |
Audit committee | ||
The audit committee represents and assists the Board in fulfilling its responsibilities for overseeing our financial reporting processes and the audit of our financial statements. | Meetings Held in 2019:
8 |
The principal duties of the audit committee include the following:
| monitoring the integrity of the Companys financial reporting process and systems of internal controls regarding finance, accounting and reporting; |
| monitoring the independence and performance of the Companys independent registered public accounting firm and internal audit function; |
| providing an avenue of communication among the Companys independent registered public accounting firm, management, the internal audit department and the Board of Directors; and |
| reviewing with management risks and practices related to cyber security, privacy and security matters. |
Compensation committee | ||
The compensation committee discharges the Boards responsibilities related to the compensation of our executives and Directors, and provides general oversight of our compensation structure, including our equity compensation plans and benefits programs. | Meetings Held in 2019:
13 |
The principal duties of the compensation committee include the following:
| to oversee and approve compensation policies and programs; |
| to review and approve corporate goals and objectives relevant to the compensation of the Companys CEO and other executive officers; |
12 | Corporate governance |
| to evaluate the performance of the CEO and recommend the compensation level of the CEO for approval by the independent members of the Board of Directors; |
| to evaluate the performance of certain executive officers and, considering the CEOs recommendations, set the compensation level for such executive officers; |
| to administer existing incentive compensation plans and equity-based plans; |
| to oversee the Companys response to regulatory developments affecting executive compensation; and |
| to review the compensation of directors. |
Nominating and corporate governance committee | ||
The Nominating and Corporate Governance Committee oversees, and represents and assists the Board in fulfilling its responsibilities relating to, our corporate governance, and Director nominations and elections. | Meetings Held in 2019:
4 |
The principal duties of the nominating and corporate governance committee include the following:
| to recommend to the Board of Directors proposed nominees for election to the Board of Directors both at annual general meetings and to fill vacancies that occur between annual general meetings; and |
| to review and make recommendations to the Board of Directors regarding the Companys corporate governance matters and practices. |
Implementation oversight committee | ||
The Implementation Oversight Committee was established on July 28, 2016, to oversee the implementation of the Federal Trade Commissions Consent Order entered into on July 16, 2016. Initially set to exist for a two-year period, unless otherwise determined by the Board, the Board amended the charter of the Implementation Oversight Committee to extend the committees existence until the committee or the Board of Directors determines otherwise. |
Meetings Held in 2019:
4 |
For more information regarding the Consent Order, see note 7, Contingencies, of the notes to consolidated financial statements included in the Companys Annual Report on Form 10-K for the year ended December 31, 2019.
Compensation committee interlocks and insider participation
Corporate governance | 13 |
Proposals to be voted on at the meeting | 15 |
Set forth below is biographical information about the 13 nominees standing for election at the Meeting, including each such persons specific experience, qualifications, attributes and skills that led our Board of Directors to conclude that such individual should serve on our Board of Directors.
THE BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT YOU VOTE FOR THE ELECTION OF EACH OF THE NOMINEES NAMED IN THIS PROXY STATEMENT TO THE BOARD OF DIRECTORS.
Nominees for Election as Directors
16 | Proposals to be voted on at the meeting |
Proposals to be voted on at the meeting | 17 |
18 | Proposals to be voted on at the meeting |
Proposals to be voted on at the meeting | 19 |
20 | Proposals to be voted on at the meeting |
Proposals to be voted on at the meeting | 21 |
22 | Proposals to be voted on at the meeting |
Proposal 3: Approve, as a special resolution, an amendment to the Companys Amended and Restated Memorandum and Articles of Association to eliminate the casting vote
THE BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS A VOTE FOR THE PROPOSED AMENDMENT OF THE COMPANYS ARTICLES TO ELIMINATE THE CASTING VOTE.
24 | Proposals to be voted on at the meeting |
Proposal 4: Approve, as a special resolution, an amendment to the Companys Amended and Restated Memorandum and Articles of Association to require the approval of two-thirds of the members of the Board of Directors then in office to amend the Companys Principles of Corporate Governance to make any changes to the responsibilities of the Chairman of the Board or the Lead Director as set forth therein
THE BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS A VOTE FOR THE PROPOSED AMENDMENT OF THE COMPANYS ARTICLES TO REQUIRE THE APPROVAL OF TWO-THIRDS OF THE MEMBERS OF THE BOARD OF DIRECTORS THEN IN OFFICE TO AMEND THE COMPANYS PRINCIPLES OF CORPORATE GOVERNANCE TO MAKE ANY CHANGES TO THE RESPONSIBILITIES OF THE CHAIRMAN OF THE BOARD OR THE LEAD DIRECTOR AS SET FORTH THEREIN.
Proposals to be voted on at the meeting | 25 |
Fees to independent registered public accounting firm for fiscal years 2019 and 2018
The following fees were for services provided by PwC:
2019 |
2018 |
|||||||
Audit fees(1) |
|
$7,007,000 |
|
|
$8,030,000 |
| ||
Audit-related fees(2) |
|
$266,000 |
|
|
$344,000 |
| ||
Tax fees(3) |
|
$1,124,000 |
|
|
$938,000 |
| ||
Total |
|
$8,397,000 |
|
|
$9,312,000 |
|
(1) | Audit fees for 2019 and 2018 consist of fees for professional services rendered for the audit of the Companys consolidated financial statements included in the Companys Annual Report on Form 10-K for the years ended December 31, 2019 and December 31, 2018, including the audit of internal controls required by Section 404 of the Sarbanes-Oxley Act of 2002, and the review of financial statements included in the Companys Quarterly Reports on Form 10-Q, and for services that are normally provided by the auditor in connection with statutory and regulatory filings or engagements and comfort letters. |
(2) | Audit-related fees consist of assurance and related services that were reasonably related to the performance of the audit or review of the Companys consolidated financial statements and which are not reported under Audit fees. |
(3) | Tax fees were for tax compliance and tax guidance. |
THE BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT YOU VOTE FOR RATIFICATION OF THE APPOINTMENT OF PwC AS THE COMPANYS INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR FISCAL YEAR 2020.
Proposals to be voted on at the meeting | 27 |
Part 4
|
Executive compensation |
Compensation discussion and analysis
This section explains the Companys 2019 executive compensation program as it relates to our named executive officers, or NEOs:
Michael O. Johnson | Chairman and Chief Executive Officer(1) | |
John Agwunobi | Co-President and Chief Health and Nutrition Officer(1) | |
John G. DeSimone | Co-President and Chief Strategic Officer(2) | |
David Pezzullo | Chief Operating Officer | |
Shin-Shing Bosco Chiu | Chief Financial Officer | |
Richard P. Goudis | Former Chief Executive Officer(3) |
(1) | As part of the Companys management succession plan, effective March 30, 2020, Mr. Johnson will step down from the Chief Executive Officer position, and Dr. Agwunobi will become the Companys Chief Executive Officer. Additionally, effective April 29, 2020, Dr. Agwunobi will become the Chairman of the Board upon his election to the Board. |
(2) | Effective March 30, 2020, Mr. DeSimone will become the Companys President. |
(3) | Mr. Goudis served as the Companys Chief Executive Officer from June 1, 2017 through January 8, 2019. |
Executive summary of our compensation program
Financial performance for purposes of our annual incentive program
The Companys financial performance is a material factor in determining the total compensation for our NEOs. As such, top-line growth stated in terms of Volume Points and profitability stated in terms of Operating Income are the performance metrics used for our annual incentive program with a weighting of 30% and 70%, respectively. These performance measures are more fully described in Annual incentive awards Targets and award determination below.
The payouts under our annual incentive award program were below target based on the Companys 2019 Volume Points and Operating Income.
Results for Bonus Purposes
|
||||||||||||||||||||
2016 | 2017 | 2018 | 2019 | 2019 Target
|
||||||||||||||||
Volume Points (millions)
|
|
5,582
|
|
|
5,379
|
|
|
5,861
|
|
|
6,069
|
|
|
6,238
|
| |||||
Operating Income ($, millions)
|
637.9 | (1) | 575.3 | (2) | 703.2 | (3) | 660.8 | (4) | 677.5 |
(1) | Operating Income for 2016 is adjusted to exclude expenses relating to challenges to the Companys business model, expenses related to regulatory inquiries, and expenses incurred for the recovery of fees relating to the re-audit of our 2010 to 2012 financial statements, or the Re-Audit. Operating Income for 2016 is also adjusted to exclude the arbitration award in connection with the Re-Audit, regulatory settlements, FTC Consent Order implementation and China grant income. |
(2) | Operating Income for 2017 is adjusted to exclude impact of the Tax Cuts and Jobs Act, or the Tax Act, expenses relating to FTC Consent Order implementation, expenses relating to regulatory inquiries, expenses relating to challenges to the Companys business model, China grant income, and impact from changes in currency exchange rates. |
(3) | Operating Income for 2018 is adjusted to exclude the impact of expenses relating to regulatory inquiries, China grant income, devaluation of the Venezuelan currency, impact from changes in currency exchange rates, and our China growth program. |
(4) | Operating Income for 2019 is adjusted to exclude expenses relating to regulatory inquiries and legal accruals, China grant income, Mexico VAT assessment, income related to finalization of insurance recoveries, impact from changes in currency exchange rates, and our China growth program. |
28 | Executive compensation |
The following table summarizes the 2019 annual incentive awards for the NEOs. All 2019 annual incentive awards to NEOs were based solely on the calculated results to target performance levels. For a more detailed discussion of our 2019 annual incentive awards for the NEOs, please refer to the discussion under Annual incentive awards & long-term incentive program Annual incentive awards.
NEO
|
Title
|
2019 Annual Incentive Award Amount | |||||
Michael O. Johnson
|
Chairman and Chief Executive Officer(1)
|
$844,795
| |||||
John Agwunobi
|
Co-President and Chief Health and Nutrition Officer(1)
|
$322,246
| |||||
John G. DeSimone
|
Co-President and Chief Strategic Officer(2)
|
$330,778
| |||||
David Pezzullo
|
Chief Operating Officer
|
$301,922
| |||||
Shin-Shing Bosco Chiu |
Chief Financial Officer |
$190,923
|
(1) | As part of the Companys management succession plan, effective March 30, 2020, Mr. Johnson will step down from the Chief Executive Officer position, and Dr. Agwunobi will become the Companys Chief Executive Officer. Additionally, effective April 29, 2020, Dr. Agwunobi will become the Chairman of the Board upon his election to the Board. |
(2) | Effective March 30, 2020, Mr. DeSimone will become the Companys President. |
Executive compensation | 29 |
* | Mr. Johnson was not granted any equity awards for his services as the Companys Chief Executive Officer in 2019. Additionally, compensation for Mr. Goudis, who resigned as the Companys Chief Executive Officer as of January 8, 2019, is not included. |
Percentages may not total 100% due to rounding.
30 | Executive compensation |
Executive compensation program objectives
As a global nutrition business, we operate in an environment of challenging regulatory, economic and geopolitical uncertainty. We manufactured approximately 60% to 65% of our own inner nutrition products that are sold through a direct selling distribution channel and generated approximately 79% of our net sales outside the United States for the year ended December 31, 2019. Our success depends on the leadership of a highly-talented, adaptive and dedicated executive team. Our executive compensation program provides competitive rewards to our NEOs who contribute to our annual success in achieving growth in revenues and profitability, as well as making strategic decisions that should lead to increasing shareholder returns over time.
Executive compensation | 31 |
The Committee believes that shareholder interests are advanced when the Company assembles, motivates and rewards a high-performing management team. To promote this objective, the Committee developed its executive compensation program guided by a pay for performance organizing framework and the resulting underlying principles listed below:
Principle |
Implication on HLF Program |
Rationale | ||
The program must attract and encourage a long-term commitment from talented executives necessary to lead our global nutrition business and advance shareholders interests in a manner consistent with our company value of operating with integrity and transparency.
|
Strong emphasis on long-term incentives and shareholder value creation.
Performance considerations reflect the Companys values and strategy and an appropriate balance of risk and reward. |
Focus on long-term performance and shareholder value helps mitigate risk and encourages growth.
Operating with integrity and transparency is a key corporate value that must be central to how we conduct our business. | ||
Compensation opportunities must be competitive with the pay practices of companies that operate in global markets and enable us to attract and retain high-performing, highly-employable executive talent with similar executive skills and capabilities. |
Peer group reflects the market in which we reasonably compete for executive talent.
We reference both proxy-sourced market data from our peer group as well as general industry survey data from Mercer (a nationally recognized compensation survey).
The Committees independent advisor provides the Committee with the 25th, 50th and 75th percentiles of market data to understand the scope of the market, with target compensation for top executives positioned relative to market references based on a variety of factors, including individual performance, internal equity, succession planning and business strategy.
Overall, our executives are within a competitive range of market, with appropriate variance based on incumbent-specific characteristics.
|
The Company recruits high-performing executives with known track records in competitive, complex and global businesses.
To attract the talent the Company needs to lead its business, compensation opportunities must be reasonably attractive to similar opportunities at our peers. | ||
A majority of total compensation is at-risk and tied to achievement of annual financial and non-financial performance goals and improvement in long-term shareholder value. |
75% of long-term incentives awarded in 2019 were performance-based and 25% were time-vesting equity (other than Mr. Goudis, who resigned from the Company in early January 2019, and Mr. Johnson, who received no equity for his services as Chief Executive Officer).
Value of PSUs align with sustained long-term shareholder value and vesting requires achievement of performance goals that support our business.
|
Annual and long-term incentive plans use growth objectives and profit objectives. These plans are forward-looking and backward-looking, to ensure a comprehensive set of metrics are used to consider overall performance of the Company and our executive team. |
32 | Executive compensation |
Principle |
Implication on HLF Program |
Rationale | ||
Incentive compensation must provide superior pay for superior performance that meets or exceeds the expectations of our shareholders. |
Superior performance expectations are built into performance targets and ranges of our incentive plans such that when incentive targets are met, the Company is exceeding peer financial performance and meeting shareholder expectations.
Our incentive plans are calibrated to deliver above-median compensation for meeting superior performance targets, and, in the case of PSUs, deriving value through increased shareholder value.
|
The only way for our executives to earn above-target compensation is by meeting or exceeding financial and non-financial goals. | ||
Incentive compensation should reflect a balanced time horizon between annual and long-term performance in order to promote sustainable growth in the value of the enterprise. |
Annual incentive is paid in cash, based on achievement of annual financial performance targets.
PSUs awarded in 2019 are earned based on achievement of the following three metrics over a performance period from January 1, 2019 to December 31, 2021: Local Currency Net Sales, Adjusted EBIT and Adjusted EPS.
|
A mix of cash and equity compensation is a competitive practice.
Paying a mix of cash and equity based on a portfolio of equity vehicles and performance metrics also helps balance risk within the pay program. | ||
Long-term incentives should be provided in Company equity, where allowed by local law, to encourage executives to plan and act with the perspective of shareholders and with the Companys vision, mission and values in mind, and be rewarded for the successful implementation of our growth strategies.
|
In 2019, long-term incentive awards granted to NEOs (other than Messrs. Johnson and Goudis) consisted of 75% PSUs and 25% RSUs.
The Company has competitive stock ownership guidelines. |
PSUs and RSUs align executive rewards with the Companys sustained long-term performance and shareholder value creation.
Encouraging equity ownership further aligns executives with sustained performance and shareholder value.
|
Executive compensation | 33 |
Purpose of compensation elements
The compensation and benefits program for our NEOs consists of and is designed to achieve the following:
Direct pay component |
Purpose | |
Base salary | Provide a competitive foundation for total compensation to each executive in consideration of job scope and responsibilities, demonstrated sustained performance, capabilities and experience.
| |
Annual cash incentives | Reward NEOs for the achievement of challenging annual financial targets that drive growth in shareholder value.
| |
Long-term equity-based incentives (PSUs and RSUs) | Provide incentives for NEOs to develop strategic plans, and make tactical decisions that will enhance shareholder value, reward NEOs with participation in the creation of sustained long-term shareholder value and encourage successful NEOs to remain with the Company.
| |
Indirect pay (benefits) |
||
Retirement benefits | Encourage NEOs to build retirement resources by providing a match on deferred compensation in the Companys 401(k) plan and Senior Executive Deferred Compensation Plan.
| |
Life insurance benefits | Provide a competitive benefit in the event of death of an executive.
| |
Severance benefits | Enable each NEO to focus his full time and attention on meeting the financial and operating objectives set by the Committee without fear of the financial consequences of an unexpected termination of employment.
| |
Change in control benefits | Enable NEOs to focus on shareholder interests when considering strategic alternatives.
|
The Chair of the Committee, with input from the independent compensation advisor, recommends the CEOs compensation to the Committee in an executive session not attended by the CEO. Once a recommendation has been established by the Committee, the CEOs compensation is reviewed with, and approved by, the independent members of the Board in an executive session.
Role of executive officers in executive compensation decisions
The CEO reviews compensation data gathered from a group of peer companies approved by the Committee and described under the subsection Peer Group, or the Herbalife Nutrition Peer Group, and, along with general industry compensation surveys, considers each executive officers performance and scope of responsibility, and makes a recommendation to the Committee on changes to base salary, annual incentive awards and equity awards for each executive officer other than himself. The CEO participates in Committee meetings at the Committees request to provide relevant background information regarding the Companys strategic objectives and to evaluate the performance of and compensation recommendations for the other executive officers. The Committee utilizes the information provided by the CEO along with input from its independent compensation advisor and the knowledge and experience of Committee members in making compensation decisions.
34 | Executive compensation |
NEO | 2018 Salary(1) | 2019 Salary | Rationale for Change | |||||||||
Michael O. Johnson |
|
$300,000 |
(2) |
|
$1,236,000 |
(3) |
Ø Continued Chief Executive Officer Role | |||||
John Agwunobi |
$525,000 | $619,000 | (4) | |||||||||
John G. DeSimone | $619,000 | $619,000 | (4) | |||||||||
David Pezzullo | $565,000 | $565,000 | (4) | |||||||||
Shin-Shing Bosco Chiu | $430,000 | $450,000 | (4) |
(1) | Base salary as of December 31, 2018. |
(2) | Base salary for services as Executive Chairman. |
(3) | On January 8, 2019, the independent members of the Board approved a base salary increase for Mr. Johnson from $300,000 to $500,000 when he assumed the role as the Companys Chief Executive Officer on a temporary basis. With Mr. Johnson continuing on as Chief Executive Officer longer than originally anticipated, the independent members of the Board subsequently approved an additional base salary increase for Mr. Johnson from $500,000 to $1,236,000, effective June 17, 2019. |
(4) | The Committee approved the base salaries for each non-CEO NEO in February 2019, including a base salary increase for Dr. Agwunobi in connection with his promotion to Co-President from $525,000 to $619,000 and a base salary increase for Mr. Chiu from $430,000 to $450,000. |
Executive compensation | 35 |
The chart below summarizes the 2019 annual incentive plan performance measures and weightings for our NEOs.
Weight in determining annual incentive | ||
Volume Points |
Operating Income | |
30%
|
70%
|
36 | Executive compensation |
The following table shows the performance targets set by the Committee with respect to 2019 and the Companys performance relative to those targets.
2019 Annual incentive plan performance targets
Target |
2019 Target
|
2019 Results
|
2019 Results as a % of target
| |||||||
Volume Points (millions)
|
|
6,238
|
|
|
6,069
|
|
97.3%
| |||
Operating income (millions)
|
$677.5 | $660.8 | (1) | 97.5% |
(1) | Operating Income presented as adjusted, as discussed below. |
For 2019, target-level bonuses were awarded for results between 95% and 108% of the applicable target. Should 95% of the applicable financial target not be achieved, there is no bonus funding or payouts to the NEOs for that metric. To align with our sales-oriented culture and our desire to continuously strive for incremental performance improvements throughout the year, beginning with performance of 95% of target, potential payouts increase in steps for each performance hurdle shown below (i.e., payouts are not interpolated for performance outcomes between two levels). The Committee determined to increase the maximum percentage to 108% in order to encourage the Companys high performance culture. This bonus scale is designed to encourage realistic target-setting and prudent risk-taking while simultaneously creating consequences for not meeting target and capping the potential payout in order to avoid excessive incentive awards as compared to performance. Our 2019 annual incentive performance (and corresponding payout) levels were established as follows:
2019 Annual incentive plan leverage
Performance Hurdles (% of Target) Volume Points and Operating Income | ||||||||||||||||||||
Threshold | Target | Maximum | ||||||||||||||||||
Below 95% |
95% | 96.25% | 97.5% | 98.75% | 100% | 102% | 104% | 106% | 108% | |||||||||||
Payout (% of Target) |
0% | 50% | 62.5% | 75% | 87.5% | 100% | 125% | 150% | 175% | 200% |
Executive compensation | 37 |
The following tables detail the Companys performance for each metric under the Annual Incentive Plan, as well as the resulting payout for each of our NEOs.
2019 Actual bonus payout detail
2019 Actual Results
Metric | Weighting | Target Performance | Actual Performance |
Actual Results (% of Target) |
||||||||||||
Volume Points (in millions) | 30% | 6,238 | 6,069 | 97.3% | ||||||||||||
Operating Income (millions) | 70% | $677.5 | $660.8 | 97.5% | ||||||||||||
Aggregate
|
100% |
2019 Payouts
Bonus Eligible Base Salary(1) |
Target Bonus | Actual Bonus | ||||||||||||||||||
Executive | (% off Salary) | $ | $ | (% of Target)(1) |
||||||||||||||||
Michael O. Johnson | $895,419 | (2) | $1,343,129 | $844,795 | 62.90% | |||||||||||||||
John Agwunobi | $603,033 | 75% | $452,275 | $322,246 | 71.25% | |||||||||||||||
John G. DeSimone | $619,000 | 75% | $464,250 | $330,778 | 71.25% | |||||||||||||||
David Pezzullo | $565,000 | 75% | $423,750 | $301,922 | 71.25% | |||||||||||||||
Shin-Shing Bosco Chiu | $446,603 | 60% | $267,962 | $190,923 | 71.25% |
(1) | Calculated using prorated salaries for Mr. Johnson, Dr. Agwunobi and Mr. Chiu. |
(2) | Target bonus for Mr. Johnson equal to 80% of base salary for the period from January 1, 2019 through June 16, 2019 ($300,000 for the period January 1, 2019 to January 7, 2019 and $500,000 for the period from January 8, 2019 through June 16, 2019), and 150% of base salary for the remainder of the 2019 year ($1,236,000 for the period from June 17, 2019 through December 31, 2019). |
Each year, the Committee determines the form of equity grant. For 2019, the Committee maintained the equity mix and the performance measures applicable to long-term incentive awards to be comprised of 75% PSUs and 25% RSUs for our NEOs (other than Mr. Goudis, who resigned from the Company in early January 2019, and Mr. Johnson, who received no equity for his services as Chief Executive Officer, as described above under Compensation program that aligns pay and performance).
Additional details of the 2019 equity awards made to our NEOs can be found below and in the tabular disclosure below under 2019 Grants of plan-based awards.
2019 Long-term incentive awards annual grant program
NEO |
PSU grant value(1)
|
Total PSUs awarded
|
RSU grant value(1)
|
Total
|
||||||||||||
Michael O. Johnson
|
|
|
|
|
|
|
|
$135,000
|
|
|
2,689
|
| ||||
John Agwunobi
|
|
$960,000
|
|
|
17,103
|
|
|
$320,000
|
|
|
5,701
|
| ||||
John G. DeSimone
|
|
$960,000
|
|
|
17,103
|
|
|
$320,000
|
|
|
5,701
|
| ||||
David Pezzullo
|
|
$900,000
|
|
|
16,034
|
|
|
$300,000
|
|
|
5,344
|
| ||||
Shin-Shing Bosco Chiu
|
|
$487,500
|
|
|
8,685
|
|
|
$162,500
|
|
|
2,895
|
|
(1) | Grant values are set by the Committee and vary slightly from amounts set forth in the 2019 Summary Compensation Table due in part to rounding down to the nearest whole unit in calculating the number of units granted on the grant date. |
38 | Executive compensation |
Executive compensation | 39 |
40 | Executive compensation |
Executive compensation | 41 |
42 | Executive compensation |
Our level of compensation for our NEOs was compared to compensation paid by the Herbalife Nutrition Peer Group. The criteria used to identify the Herbalife Nutrition Peer Group were: (1) principal operations in the U.S. with an international presence we operate in 94 countries around the world in a highly regulated business where approximately 79% of our net sales for the year ended December 31, 2019, were generated outside of the United States; (2) financial scope our management talent should be similar to that of companies of a similar size in terms of revenues and market capitalization; (3) industry we compete for talent with other companies in consumer product related industries; and (4) common peer of peers we examined companies that are most frequently considered peers by Herbalife Nutritions peers. Annually, the Committee reviews the peer group and updates the group as appropriate.
With respect to pay decisions regarding 2019 NEO compensation, the industry peer group was comprised of the seventeen (17) companies listed below. All of the peer companies were within the range of approximately 50% and 200% of Herbalifes trailing twelve-month revenues at the time the peer group was established in July 2018. The peer group median revenue of $5.7 billion and median market capitalization of $9.6 billion, in each case at the time the Herbalife Nutrition Peer Group was established, were comparable to those of Herbalife Nutrition. During this period, the Herbalife Nutrition Peer Group consisted of the following:
Company | Industry |
Revenue
|
Market capitalization* ($ millions) |
|||||||
Avon Products Inc.
|
Personal Products
|
|
$4,951
|
|
|
$2,501
|
| |||
Campbell Soup Co
|
Packaged Foods and Meats
|
|
$8,088
|
|
|
$14,908
|
| |||
Church & Dwight Inc.
|
Household Products
|
|
$4,358
|
|
|
$17,262
|
| |||
The Clorox Company
|
Household Products
|
|
$6,133
|
|
|
$19,270
|
| |||
Conagra Brands, Inc.
|
Packaged Foods and Meats
|
|
$10,532
|
|
|
$16,663
|
| |||
Coty Inc.
|
Personal Products
|
|
$8,394
|
|
|
$8,526
|
| |||
Dr Pepper Snapple Group, Inc.
|
Soft Drinks
|
|
$
|
(1)
|
|
$
|
(1)
| |||
Edgewell Personal Care Co
|
Personal Products
|
|
$2,138
|
|
|
$1,681
|
| |||
Hain Celestial Group Inc.
|
Packaged Foods and Meats
|
|
$2,239
|
|
|
$2,708
|
| |||
International Flavors & Fragrances
|
Specialty Chemicals
|
|
$5,140
|
|
|
$13,776
|
| |||
The J.M. Smucker Company
|
Packaged Foods and Meats
|
|
$7,651
|
|
|
$11,877
|
| |||
McCormick & Co, Inc.
|
Packaged Foods and Meats
|
|
$5,347
|
|
|
$22,572
|
| |||
Nu Skin Enterprises Inc.
|
Personal Products
|
|
$2,420
|
|
|
$2,276
|
| |||
Post Holdings Inc.
|
Packaged Foods and Meats
|
|
$5,727
|
|
|
$7,715
|
| |||
Spectrum Brands Holdings, Inc.
|
Household Products
|
|
$3,793
|
|
|
$3,139
|
| |||
TreeHouse Foods, Inc.
|
Packaged Foods and Meats
|
|
$4,289
|
|
|
$2,726
|
| |||
Tupperware Brands Corp
|
Housewares and Specialties
|
|
$1,887
|
|
|
$420
|
| |||
Herbalife Nutrition Ltd.
|
Personal Products
|
|
$4,877
|
|
|
$6,545
|
| |||
Percentile Rank |
|
46 |
% |
|
45 |
% |
* | As of December 31, 2019. |
(1) | As of July 2018, Dr Pepper Snapple Group, Inc. became a business unit of Keurig Dr Pepper. |
Executive compensation | 43 |
After reviewing the peer group in July 2019, Dr. Pepper Snapple Group was removed from the Herbalife Nutrition Peer Group due to acquisition. For 2020 pay decisions, the Herbalife Nutrition Peer Group will consist of the following:
Company | Industry |
Revenue
|
Market capitalization* ($ millions) |
|||||||
Avon Products Inc.
|
Personal Products
|
|
$4,951
|
|
|
$2,501
|
| |||
Campbell Soup Co
|
Packaged Foods and Meats
|
|
$8,088
|
|
|
$14,908
|
| |||
Church & Dwight Inc.
|
Household Products
|
|
$4,358
|
|
|
$17,262
|
| |||
The Clorox Company
|
Household Products
|
|
$6,133
|
|
|
$19,270
|
| |||
Conagra Brands, Inc.
|
Packaged Foods and Meats
|
|
$10,532
|
|
|
$16,663
|
| |||
Coty Inc.
|
Personal Products
|
|
$8,394
|
|
|
$8,526
|
| |||
Edgewell Personal Care Co
|
Personal Products
|
|
$2,138
|
|
|
$1,681
|
| |||
Hain Celestial Group Inc.
|
Packaged Foods and Meats
|
|
$2,239
|
|
|
$2,708
|
| |||
International Flavors & Fragrances
|
Specialty Chemicals
|
|
$5,140
|
|
|
$13,776
|
| |||
The J.M. Smucker Company
|
Packaged Foods and Meats
|
|
$7,651
|
|
|
$11,877
|
| |||
McCormick & Co, Inc.
|
Packaged Foods and Meats
|
|
$5,347
|
|
|
$22,572
|
| |||
Nu Skin Enterprises Inc.
|
Personal Products
|
|
$2,420
|
|
|
$2,276
|
| |||
Post Holdings Inc.
|
Packaged Foods and Meats
|
|
$5,727
|
|
|
$7,715
|
| |||
Spectrum Brands Holdings, Inc.
|
Household Products
|
|
$3,793
|
|
|
$3,139
|
| |||
TreeHouse Foods, Inc.
|
Packaged Foods and Meats
|
|
$4,289
|
|
|
$2,726
|
| |||
Tupperware Brands Corp
|
Housewares and Specialties
|
|
$1,887
|
|
|
$420
|
| |||
Herbalife Nutrition Ltd.
|
Personal Products
|
|
$4,877
|
|
|
$6,545
|
| |||
Percentile Rank |
46 | % | 45 | % |
* | As of December 31, 2019. |
44 | Executive compensation |
Executive compensation | 45 |
Executive officers of the registrant
NEO
|
Age
|
Position with the company
|
Officer since
| |||||
Michael O. Johnson
|
|
65
|
|
Chairman and Chief Executive Officer(1)
|
2003
| |||
Dr. John Agwunobi
|
|
55
|
|
Co-President, Chief Health and Nutrition Officer(1)
|
2018
| |||
John DeSimone
|
|
53
|
|
Co-President, Chief Strategic Officer(2)
|
2009
| |||
David Pezzullo
|
|
54
|
|
Chief Operating Officer
|
2014
| |||
Shin-Shing Bosco Chiu
|
|
53
|
|
Chief Financial Officer
|
2010
| |||
Alan Hoffman
|
|
53
|
|
Executive Vice President, Global Corporate Affairs
|
2014
| |||
Robert Levy
|
|
61
|
|
Executive Vice President, Worldwide Distributor Affairs and Latin America
|
2004
| |||
Henry Wang
|
|
50
|
|
Executive Vice President, General Counsel and Corporate Secretary
|
2018
| |||
Edi Hienrich
|
|
58
|
|
Senior Vice President and Managing Director, EMEA and India
|
2009
| |||
Thomas Harms
|
|
58
|
|
Senior Vice President and Managing Director, China and APAC
|
2017
| |||
Alexander Amezquita
|
|
46
|
|
Senior Vice President, Finance, Strategy and Investor Relations
|
2017
|
(1) | As part of the Companys management succession plan, effective March 30, 2020, Mr. Johnson will step down from the Chief Executive Officer position, and Dr. Agwunobi will become the Companys Chief Executive Officer. Additionally, effective April 29, 2020, Dr. Agwunobi will become the Chairman of the Board upon his election to the Board. |
(2) | Effective March 30, 2020, Mr. DeSimone will become the Companys President. |
46 | Executive compensation |
Executive compensation | 47 |
2019 Summary compensation table
The following table sets forth the total compensation for the fiscal years ended December 31, 2019, 2018 and 2017, of the Companys Chief Executive Officer, Chief Financial Officer, and each of the three other most highly compensated executive officers*:
Name and principal position |
Year |
Salary ($) |
Stock ($)(1) |
Option awards ($)(1) |
Non-equity incentive plan compensation ($)(2) |
All other compensation ($) |
Total ($) |
|||||||||||||||||||||
Michael Johnson |
2019 | 873,692 | 134,988 | | 844,795 | 229,483 | (3) | 2,082,958 | ||||||||||||||||||||
Chief Executive Officer |
2018 | 436,346 | 134,987 | | 658,296 | 16,711 | 1,246,340 | |||||||||||||||||||||
2017 | 902,356 | | 2,500,012 | 1,618,172 | 330,392 | 5,350,932 | ||||||||||||||||||||||
Dr. John Agwunobi* |
2019 | 600,923 | 1,279,989 | | 322,246 | 21,662 | (4) | 2,224,820 | ||||||||||||||||||||
Co-President and Chief
|
2018 | 506,589 | 1,279,829 | | 576,841 | 18,537 | 2,381,796 | |||||||||||||||||||||
| | | | | | | ||||||||||||||||||||||
John G. DeSimone |
2019 | 619,000 | 1,279,989 | | 330,778 | 46,001 | (5) | 2,275,768 | ||||||||||||||||||||
Co-President and Chief
|
2018 | 619,000 | 1,279,829 | | 858,863 | 72,487 | 2,830,179 | |||||||||||||||||||||
2017 | 619,000 | | 1,735,021 | 365,597 | 22,552 | 2,742,170 | ||||||||||||||||||||||
David Pezzullo |
2019 | 565,000 | 1,199,947 | | 301,922 | 44,063 | (6) | 2,110,932 | ||||||||||||||||||||
Chief Operating Officer |
2018 | 551,850 | 1,199,915 | | 765,691 | 45,161 | 2,562,617 | |||||||||||||||||||||
2017 | 485,699 | 549,976 | 683,251 | 310,078 | 21,402 | 2,050,407 | ||||||||||||||||||||||
Shin-Shing Bosco Chiu* Chief Financial Officer |
2019 | 446,154 | 649,985 | | 190,923 | 16,245 | (7) | 1,303,307 | ||||||||||||||||||||
2018 | 409,198 | 649,839 | | 409,599 | 15,123 | 1,483,759 | ||||||||||||||||||||||
| | | | | | | ||||||||||||||||||||||
Richard Goudis(8) |
2019 | 46,154 | | | | 1,535 | (9) | 47,689 | ||||||||||||||||||||
Former Chief Executive Officer |
2018 | 1,000,000 | 4,999,963 | | | 102,362 | 6,102,325 | |||||||||||||||||||||
2017 | 873,689 | 3,193,983 | 1,806,020 | 735,110 | 31,243 | 6,640,045 |
* | Dr. Agwunobi and Mr. Chiu were NEOs for the first time in fiscal year 2018. Accordingly, only information relating to their fiscal years 2018 and 2019 compensation is included in the compensation tables and related discussions of NEO compensation. |
(1) | Amounts represent the aggregate grant date fair value of the relevant award(s) presented in accordance with ASC Topic 718, Compensation Stock Compensation. See note 9 of the notes to consolidated financial statements included in the Companys Annual Report on Form 10-K for the year ended December 31, 2019 regarding assumptions underlying valuation of equity awards. For the 2019 PSU grants, the grant date fair values of such awards, assuming performance at the maximum level would be $1,919,983 for each of Dr. Agwunobi and Mr. DeSimone, $1,799,977 for Mr. Pezzullo and $974,978 for Mr. Chiu. |
(2) | Incentive plan amounts determined as more specifically discussed under Compensation discussion and analysis Annual incentive awards & long-term incentive program Targets and award determination. |
(3) | Amounts disclosed in this column for Mr. Johnson include: (i) $20,779 in deferred compensation which represents the Companys matching contribution earned in 2019 but credited to Mr. Johnsons account in 2020; (ii) $630 in Company-paid premiums for executive life insurance; (iii) $9,800 in Company-paid 401(k) matching contributions; (iv) $110,526 attributable to personal use of private aircraft; and (v) $65,047 for authorized spousal travel expenses related to distributor events pursuant to the Companys Senior Executive Event Travel Policy and $22,701 in tax gross-ups related thereto. |
(4) | Dr. Agwunobis other compensation includes: (i) $11,232 in deferred compensation which represents the Companys matching contribution earned in 2019 but credited to Dr. Agwunobis account in 2020; (ii) $630 in Company-paid premiums for executive life insurance; and (iii) $9,800 in Company paid 401(k) matching contributions. |
(5) | Amounts disclosed in this column for Mr. DeSimone include: (i) $11,865 in deferred compensation which represents the Companys matching contribution earned in 2019 but credited to Mr. DeSimones account in 2020; (ii) $630 in Company-paid premiums for executive life insurance; (iii) $9,800 in Company-paid 401(k) matching contributions; and (iv) $16,369 for authorized spousal travel expenses related to distributor events pursuant to the Companys Senior Executive Event Travel Policy and $7,337 in tax gross-ups related thereto. |
(6) | Amounts disclosed in this column for Mr. Pezzullo include: (i) $9,975 in deferred compensation which represents the Companys matching contribution earned in 2019 but credited to Mr. Pezzullos account in 2020; (ii) $630 in Company-paid premiums for executive life insurance; (iii) $9,800 in Company-paid 401(k) matching contributions; and (iv) $16,336 for authorized spousal travel expenses related to distributor events pursuant to the Companys Senior Executive Event Travel Policy and $7,322 in tax gross-ups related thereto. |
48 | Executive compensation |
(7) | Amounts disclosed in this column for Mr. Chiu include: (i) $5,815 in deferred compensation which represents the Companys matching contribution earned in 2019 but credited to Mr. Chius account in 2020; (ii) $630 in Company-paid premiums for executive life insurance; and (iii) $9,800 in Company paid 401(k) matching contributions. |
(8) | Mr. Goudis resigned as the Companys Chief Executive Officer as of January 8, 2019. |
(9) | Amount disclosed in this column for Mr. Goudis reflects Company-paid 401(k) matching contributions. |
2019 Grants of plan-based awards
The following table sets forth all grants of plan-based awards made to the NEOs during the fiscal year ended December 31, 2019. For further discussion regarding the grants see Compensation discussion and analysis Annual incentive awards and long-term incentive awards Long-term incentive awards.
NEO | Grant Date(1) |
Estimated future payouts under non-equity incentive plan awards |
Estimated future payouts under equity incentive plan awards(1) |
All other stock awards: number of shares or |
Exercise of base price of SAR Awards ($/share) |
Grant date fair value of Stock ($) |
||||||||||||||||||||||||||||||
Target ($) |
Maximum ($) |
Threshold (#) |
Target (#) |
Maximum (#) |
||||||||||||||||||||||||||||||||
Michael Johnson |
|
1,343,129 |
(3) |
|
2,686,258 |
(3) |
||||||||||||||||||||||||||||||
|
05/06/2019 |
|
|
2,689 |
|
|
2,689 |
|
|
2,689 |
|
|
|
|
|
|
|
|
134,988 |
| ||||||||||||||||
John Agwunobi |
|
452,275 |
(4) |
|
904,550 |
(4) |
||||||||||||||||||||||||||||||
|
02/21/2019 |
|
|
14,252 |
|
|
22,804 |
|
|
39,907 |
|
|
|
|
|
|
|
|
2,239,980 |
| ||||||||||||||||
John G. DeSimone |
|
464,250 |
|
|
928,500 |
|
||||||||||||||||||||||||||||||
|
02/21/2019 |
|
|
14,252 |
|
|
22,804 |
|
|
39,907 |
|
|
|
|
|
|
|
|
2,239,980 |
| ||||||||||||||||
David Pezzullo |
|
423,750 |
|
|
847,500 |
|
||||||||||||||||||||||||||||||
|
02/21/2019 |
|
|
13,361 |
|
|
21,378 |
|
|
37,412 |
|
|
|
|
|
|
|
|
2,099,936 |
| ||||||||||||||||
Shin-Shing Bosco Chiu |
|
267,962 |
(5) |
|
535,924 |
(5) |
||||||||||||||||||||||||||||||
|
02/21/2019 |
|
|
7,237 |
|
|
11,580 |
|
|
20,265 |
|
|
|
|
|
|
|
|
1,137,474 |
| ||||||||||||||||
Richard Goudis(6) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) | All equity grants to NEOs, other than Mr. Johnson, were approved by the Committee in February 2019. The equity grant to Mr. Johnson, as Chairman of the Board, was approved by the independent members of the Board in April 2019. All equity grants reflected in this table were made under the 2014 Stock Incentive Plan. |
(2) | For the 2019 PSU grants, the grant date fair value above was calculated assuming performance at the maximum level. |
(3) | Estimated future payouts for Mr. Johnson are based upon a prorated bonus eligible salary of $895,419. |
(4) | Estimated future payouts for Dr. Agwunobi are based upon a prorated bonus eligible salary of $603,033. |
(5) | Estimated future payouts for Mr. Chiu are based upon a prorated bonus eligible salary of $446,603. |
(6) | Mr. Goudis resigned as the Companys Chief Executive Officer as of January 8, 2019. |
Executive compensation | 49 |
50 | Executive compensation |
Outstanding equity awards at 2019 fiscal year-end
The following table sets forth equity awards of the NEOs outstanding as of December 31, 2019.
NEO | Grant Date |
Option/Stock Appreciation Right Awards
|
Stock Unit Awards
|
|||||||||||||||||||||||||
Number of securities underlying unexercised options/SARs (#) exercisable |
Equity incentive plan awards: number of securities unexercised options/SARs (#)
|
Exercise Price ($) |
Expiration date |
Equity incentive plan awards: number of unearned stock units or other rights that have not vested (#) |
Equity incentive plan awards: market or payout value of unearned shares, units or other rights that have not vested ($) |
|||||||||||||||||||||||
Michael Johnson | 12/19/2013 | 302,662 | 39.79 | 12/19/2023 | (1) | |||||||||||||||||||||||
05/09/2016 | 335,908 | 31.255 | 05/09/2026 | (1) | ||||||||||||||||||||||||
02/27/2017 | 70,620 | 105,932 | 28.595 | 02/27/2027 | (2) | |||||||||||||||||||||||
05/06/2019 | 2,689 | (3) | $128,185 | |||||||||||||||||||||||||
John Agwunobi | 02/29/2016 | 55,324 | 27.375 | 02/28/2026 | (1) | |||||||||||||||||||||||
02/27/2017 | 8,474 | 12,172 | 28.595 | 02/27/2027 | (4) | |||||||||||||||||||||||
02/26/2018 | 22,246 | (5) | $1,060,467 | |||||||||||||||||||||||||
02/26/2018 | 5,932 | (6) | $282,778 | |||||||||||||||||||||||||
02/21/2019 | 17,103 | (7) | $815,300 | |||||||||||||||||||||||||
02/21/2019 | 5,701 | (6) | $271,767 | |||||||||||||||||||||||||
John G. DeSimone | 05/09/2016 | 116,560 | 31.255 | 05/09/2026 | (1) | |||||||||||||||||||||||
02/27/2017 | 49,012 | 73,516 | 28.595 | 02/27/2027 | (2) | |||||||||||||||||||||||
02/26/2018 | 22,246 | (5) | $1,060,467 | |||||||||||||||||||||||||
02/26/2018 | 5,932 | (6) | $282,778 | |||||||||||||||||||||||||
02/21/2019 | 17,103 | (7) | $815,300 | |||||||||||||||||||||||||
02/21/2019 | 5,701 | (6) | $271,767 | |||||||||||||||||||||||||
David Pezzullo | 05/18/2011 | 20,764 | 26.645 | 05/18/2021 | (1) | |||||||||||||||||||||||
03/01/2012 | 6,816 | 33.85 | 03/01/2022 | (1) | ||||||||||||||||||||||||
12/19/2013 | 29,508 | 39.79 | 12/19/2023 | (1) | ||||||||||||||||||||||||
05/09/2016 | 43,668 | 31.255 | 05/09/2026 | (1) | ||||||||||||||||||||||||
02/27/2017 | 18,360 | 27,542 | 28.595 | 02/27/2027 | (2) | |||||||||||||||||||||||
08/03/2017 | 16,806 | (8) | $801,142 | |||||||||||||||||||||||||
02/26/2018 | 20,856 | (5) | $994,206 | |||||||||||||||||||||||||
02/26/2018 | 5,562 | (6) | $265,141 | |||||||||||||||||||||||||
02/21/2019 | 16,034 | (7) | $764,341 | |||||||||||||||||||||||||
02/21/2019 | 5,344 | (6) | $254,748 | |||||||||||||||||||||||||
Shin-Shing Bosco Chiu | 12/19/2013 | 24,212 | 39.79 | 12/19/2023 | (1) | |||||||||||||||||||||||
05/07/2015 | 42,500 | 23.90 | 05/07/2025 | (1) | ||||||||||||||||||||||||
05/09/2016 | 15,450 | 31.255 | 05/09/2026 | (1) | ||||||||||||||||||||||||
02/27/2017 | 6,496 | 9,746 | 28.595 | 02/27/2027 | (2) | |||||||||||||||||||||||
02/26/2018 | 11,296 | (5) | $538,480 | |||||||||||||||||||||||||
02/26/2018 | 3,012 | (6) | $143,582 | |||||||||||||||||||||||||
02/21/2019 | 8,685 | (7) | $414,014 | |||||||||||||||||||||||||
02/21/2019 | 2,895 | (6) | $138,005 | |||||||||||||||||||||||||
Richard P. Goudis(9) | | | | | | | |
(1) | These SARS fully vested on December 31, 2019. |
(2) | These SARs fully vested in February 2020, three years from the grant date, and were subject to potential, partial early vesting, provided that the applicable sales leader retention performance criteria were met. |
(3) | Subject to continued Company service, these RSUs vest 100% on April 15, 2020. |
(4) | Subject to continued Company service, these SARs vest annually, 20% on the first anniversary, 20% on the second anniversary and 60% on the third anniversary of the grant date. |
(5) | These PSUs vest 100% on December 31, 2020 subject to continued employment and provided that the applicable performance criteria are met. The number of PSUs reflected assumes a target level of performance. |
(6) | Subject to continued Company service, these RSUs vest annually, 20% on the first anniversary, 20% on the second anniversary and 60% on the third anniversary of the grant date. |
(7) | Subject to continued employment, these PSUs vest 100% on December 31, 2021 provided that the applicable performance criteria are met. The number of PSUs reflected assumes a target level of performance. |
(8) | Subject to continued employment, these PSUs vest 100% on December 31, 2019, provided that the applicable performance criteria are met. The number of PSUs reflected assumes a target level of performance. |
(9) | Pursuant to the terms of the Separation Agreement, Mr. Goudis forfeited all equity grants issued in 2018 in addition to all other unvested equity grants. Additional details of the Separation Agreement can be found above under Employment and severance agreements. |
Executive compensation | 51 |
2019 Option exercises and stock vested
The following table sets forth information with respect to Common Shares acquired upon the exercise of stock options and the vesting of stock awards of the NEOs during the fiscal year ended December 31, 2019.
NEO | Option awards | Stock awards | ||||||||||||||
Number of shares acquired on exercise (#)
|
Value realized on exercise ($)
|
Number of shares acquired on vesting (#)
|
Value realized on vesting ($)
|
|||||||||||||
Michael Johnson |
|
|
|
|
2,390 |
|
124,878 |
| ||||||||
Dr. John Agwunobi |
|
|
|
|
1,482 |
|
83,763 |
| ||||||||
John G. DeSimone |
|
|
|
|
1,482 |
|
83,763 |
| ||||||||
David Pezzullo |
|
|
|
|
1,390 |
|
78,563 |
| ||||||||
Shin-Shing Bosco Chiu |
|
|
|
|
752 |
|
42,503 |
| ||||||||
Richard Goudis |
|
|
|
|
|
|
|
|
2019 Non-qualified deferred compensation table
The following table sets forth all non-qualified deferred compensation of the NEOs for the fiscal year ended December 31, 2019 pursuant to the Herbalife International of America, Inc. Senior Executive Deferred Compensation Plan, effective January 1, 1996, as amended and restated, or the Senior Executive Plan.
NEO |
Executive contributions in last FY ($)
|
Company contributions in last FY ($)(1)
|
Aggregate earnings in last FY ($)
|
Aggregate withdrawals/ distribution ($)
|
Aggregate balance at last FYE ($)(2)
|
|||||||||||||
Michael Johnson | 34,948 | 20,779 | 52,840 | | 1,842,337 | |||||||||||||
Dr. John Agwunobi | 233,144 | 11,232 | 47,616 | | 334,203 | |||||||||||||
John G. DeSimone | 30,950 | 11,865 | 95,723 | | 501,037 | |||||||||||||
David Pezzullo | 99,169 | 9,975 | 126,864 | 80,057 | 1,195,275 | |||||||||||||
Shin Shing Bosco Chiu | 17,846 | 5,815 | 16,708 | | 586,872 | |||||||||||||
Richard Goudis | 2,308 | | 138,806 | | 982,667 |
(1) | Amounts reported as compensation in All Other Compensation in the 2019 Summary Compensation Table. Each amount represents contributions earned in 2019 but credited to the NEOs account in 2020 and thus not part of the Aggregate balance at last FYE. |
(2) | Amounts include the following, which have been included in the Summary Compensation Table of the Companys previously filed proxy statements: $1,253,514 for Mr. Johnson for the reported years 2003 to 2017; $58,634 for Dr. Agwunobi for the reported year 2018; $305,498 for Mr. DeSimone for the reported years 2010 to 2018; $0 for Mr. Pezzullo for the reported year 2017 to 2018; $20,982 for Mr. Chiu for the reported year 2018; and $635,211 for Mr. Goudis for the reported years 2006 to 2018. |
52 | Executive compensation |
Executive compensation | 53 |
54 | Executive compensation |
Executive compensation | 55 |
56 | Executive compensation |
The table below sets forth the estimated value of the potential payments to each of our NEOs, assuming the executives employment had terminated on December 31, 2019 and/or that a change in control of the Company had also occurred on that date. Amounts are reported without any reduction for possible delay in the commencement or timing of payments.
NEO |
Termination without cause or with good reason not in connection with a change in control
|
Termination without cause or with good reason in connection with a change in
control
|
Change in control (without termination)(1) ($)
|
Death or Disability ($)
|
||||||||||||
Michael Johnson |
||||||||||||||||
Severance(2) |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Bonus(3) |
|
844,795 |
|
|
844,795 |
|
|
|
|
|
844,795 |
| ||||
Equity acceleration(4) |
|
|
|
|
2,020,653 |
|
|
2,020,653 |
|
|
|
| ||||
Outplacement service |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Medical coverage |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Life insurance |
|
|
|
|
|
|
|
|
|
|
1,000,000 |
| ||||
Dr. John Agwunobi |
||||||||||||||||
Severance(2) |
|
619,000 |
|
|
619,000 |
|
|
|
|
|
|
| ||||
Bonus(3) |
|
322,246 |
|
|
322,246 |
|
|
|
|
|
322,246 |
| ||||
Equity acceleration(4) |
|
|
|
|
2,672,793 |
|
|
2,672,793 |
|
|
|
| ||||
Outplacement service |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Medical coverage |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Life insurance |
|
|
|
|
|
|
|
|
|
|
1,000,000 |
| ||||
John G. DeSimone |
||||||||||||||||
Severance(2) |
|
1,238,000 |
|
|
1,238,000 |
|
|
|
|
|
|
| ||||
Bonus(3) |
|
330,778 |
|
|
330,778 |
|
|
|
|
|
330,778 |
| ||||
Equity acceleration(4) |
|
|
|
|
3,832,629 |
|
|
3,832,629 |
|
|
|
| ||||
Outplacement service |
|
20,000 |
|
|
20,000 |
|
|
|
|
|
|
| ||||
Medical coverage |
|
41,901 |
|
|
41,901 |
|
|
|
|
|
|
| ||||
Life insurance |
|
|
|
|
|
|
|
|
|
|
1,000,000 |
| ||||
David Pezzullo |
||||||||||||||||
Severance(2) |
|
565,000 |
|
|
565,000 |
|
|
|
|
|
|
| ||||
Bonus(3) |
|
301,922 |
|
|
301,922 |
|
|
|
|
|
301,922 |
| ||||
Equity acceleration(4) |
|
|
|
|
2,803,799 |
|
|
2,803,799 |
|
|
|
| ||||
Outplacement service |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Medical coverage |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Life insurance |
|
|
|
|
|
|
|
|
|
|
1,000,000 |
| ||||
Shin Shing Bosco Chiu |
||||||||||||||||
Severance(2) |
|
450,000 |
|
|
450,000 |
|
|
|
|
|
|
| ||||
Bonus(3) |
|
190,923 |
|
|
190,923 |
|
|
|
|
|
190,923 |
| ||||
Equity acceleration(4) |
|
|
|
|
1,419,986 |
|
|
1,419,986 |
|
|
|
| ||||
Outplacement service |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Medical coverage |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Life insurance |
|
|
|
|
|
|
|
|
|
|
1,000,000 |
|
(1) | With respect to PSUs held by Dr. Agwunobi and Messrs. Pezzullo and Chiu, the reported amounts assume the Committee exercised its discretion to accelerate the awards. |
(2) | Based on salary as of December 31, 2019. |
(3) | Represents bonus amounts earned in 2019, as disclosed in the Non-Equity Incentive Plan Compensation column of the 2019 Summary Compensation Table. Per the terms of the Severance Plan, as described in this section, upon a termination of his employment by the Company without Cause (other than due to death or disability) or by him for Good Reason each of Messrs. Chiu and Pezzullo and Dr. Agwunobi are entitled to a pro rata bonus for the year in which the termination occurs based on the Companys actual results for the entire year. Per the terms of the DeSimone Severance Agreement, as described above, upon a termination of his employment by the Company without Cause or by him for Good Reason, or due to death or disability, Mr. DeSimone is entitled to a pro rata bonus for the year in which termination occurs based on the Companys actual results for the entire year. |
(4) | Amounts with respect to accelerated vesting of stock awards were based on the closing price of a Common Share on the NYSE on December 31, 2019 of $47.67. |
Executive compensation | 57 |
Part 5
|
Security ownership of certain beneficial owners and management |
The following table sets forth the beneficial ownership of Common Shares as of March 2, 2020, the Record Date, of (1) each director, (2) each of the named executive officers, (3) all directors and executive officers as a group and (4) each person or entity known to the Company to beneficially own more than five percent (5%) of outstanding Common Shares. The Common Shares are the Companys only class of voting securities that are issued and outstanding.
Beneficial ownership is determined in accordance with the rules of the SEC and includes voting and investment power with respect to Common Shares. Except as otherwise indicated below, to our knowledge, all persons listed below have sole voting and investment power with respect to their Common Shares, except to the extent authority is shared by spouses under applicable law. Common Shares subject to stock options, warrants and other equity awards that are exercisable or have vested or will become exercisable or vest within 60 days of March 2, 2020 are considered outstanding and beneficially owned by the person holding the security for the purpose of computing the percentage ownership of that person, but are not treated as outstanding for the purpose of computing the percentage ownership of any other person.
Name of beneficial owner |
Amount and nature of beneficial ownership
|
Percentage ownership(1) |
||||||
Directors |
||||||||
Dr. Richard Carmona(2) |
|
21,267 |
|
|
* |
| ||
Jonathan Christodoro(2) |
|
21,267 |
|
|
* |
| ||
Hunter C. Gary(2) |
|
21,267 |
|
|
* |
| ||
Nicholas Graziano(2) |
|
5,079 |
|
|
* |
| ||
Alan LeFevre(2) |
|
9,079 |
|
|
* |
| ||
Jesse A. Lynn(2) |
|
21,267 |
|
|
* |
| ||
Juan Miguel Mendoza(2) |
|
5,079 |
|
|
* |
| ||
Michael Montelongo(2) |
|
17,267 |
|
|
* |
| ||
James L. Nelson(3) |
|
21,922 |
|
|
* |
| ||
Maria Otero(2) |
|
18,067 |
|
|
* |
| ||
Margarita Paláu-Hernández(2) |
|
5,079 |
|
|
* |
| ||
John Tartol(2) |
|
382,479 |
|
|
* |
| ||
Named executive officers |
||||||||
Michael O. Johnson(4) |
|
2,379,294 |
|
|
1.73% |
| ||
Dr. John Agwunobi(5) |
17,302 | * | ||||||
John G. DeSimone(6) |
|
408,613 |
|
|
* |
| ||
David Pezzullo(7) |
|
185,682 |
|
|
* |
| ||
Shin-Shing Bosco Chiu(8) |
|
37,069 |
|
|
* |
| ||
Richard Goudis(9) |
|
803,489 |
|
|
* |
| ||
All directors and executive officers as a group (23 persons)(10) |
4,280,902 | 3.10% | ||||||
Greater than 5% beneficial owners |
||||||||
Capital Research Global Investors(11) |
|
18,537,804 |
|
|
13.46% |
| ||
Carl C. Icahn(12) |
35,227,904 | 25.59% | ||||||
Deccan Value Investors L.P.(13) |
|
10,429,442 |
|
|
7.58% |
| ||
The Vanguard Group(14) |
|
9,663,675 |
|
|
7.02% |
| ||
Renaissance Technologies LLC(15) |
|
8,561,703 |
|
|
6.22% |
| ||
HBL Swiss Services GmbH(16) |
|
10,025,020 |
|
|
7.28% |
(17) |
Security ownership of certain beneficial owners and management | 59 |
* | Less than 1% security ownership by certain beneficial owners and management. |
(1) | Applicable percentage is based upon 137,676,193 Common Shares outstanding as of March 2, 2020, which pursuant to Instruction 1 to Item 403 of Regulation S-K, excludes 10,025,020 Common Shares held by HBL Swiss Services GmbH, an indirect wholly-owned subsidiary of the Company, which are considered to be outstanding under Cayman Islands law and carry voting and other share rights related to ownership of our Common Shares, which may be exercised. |
(2) | Includes 2,689 RSUs with restrictions that may lapse and be paid in Common Shares within 60 days of March 2, 2020. |
(3) | Includes 3,344 RSUs with restrictions that may lapse and be paid in Common Shares within 60 days of March 2, 2020. |
(4) | Mr. Johnson is also a director. Includes 512,460 SARs equivalent to 59,317 Common Shares which have vested or will vest and become exercisable and 2,689 RSUs with restrictions that may lapse and be paid in Common Shares, in each case within 60 days of March 2, 2020. |
(5) | Dr. Agwunobi is also a director nominee. Includes 76,510 SARs equivalent to 14,710 Common Shares which have vested or will vest and become exercisable within 60 days of March 2, 2020. |
(6) | Includes 239,088 SARs equivalent to 30,787 Common Shares which have vested or will vest and become exercisable within 60 days of March 2, 2020. |
(7) | Includes 117,150 SARs equivalent to 16,262 Common Shares which have vested or will vest and become exercisable within 60 days of March 2, 2020 and 84,132 vested but deferred RSUs that are convertible to Common Shares. |
(8) | Includes 74,192 SARs equivalent to 16,794 Common Shares which have vested or will vest and become exercisable within 60 days of March 2, 2020. |
(9) | Mr. Goudis resigned as the Companys Chief Executive Officer as of January 8, 2019. |
(10) | Includes 1,593,752 SARs equivalent to 296,913 Common Shares which have vested or will vest and become exercisable within 60 days of March 2, 2020, 35,612 RSUs with restrictions that may lapse and be paid in Common Shares within 60 days of March 2, 2020 and 235,632 vested but deferred RSUs that are convertible to Common Shares. |
(11) | The information regarding the beneficial ownership of Capital Research Global Investors is based on the Schedule 13G/A filed with the SEC by Capital Research Global Investors on February 14, 2020. According to this Schedule 13G/A, Capital Research Global Investors has (i) sole power to vote 18,537,425 Common Shares, (ii) shared power to vote 0 Common Shares, (iii) sole power to dispose of 18,537,804 Common Shares and (iv) shared power to dispose of 0 Common Shares. The address for Capital Research Global Investors is 333 South Hope Street, Los Angeles, CA 90071. |
(12) | The information regarding the beneficial ownership of Carl C. Icahn is based on the Schedule 13D/A filed jointly with the SEC by High River Limited Partnership (High River), Hopper Investments LLC (Hopper), Barberry Corp. (Barberry), Icahn Partners Master Fund LP (Icahn Master), Icahn Offshore LP (Icahn Offshore), Icahn Partners LP (Icahn Partners), Icahn Onshore LP (Icahn Onshore), Icahn Capital LP (Icahn Capital), IPH GP LLC (IPH), Icahn Enterprises Holdings L.P. (Icahn Enterprises Holdings), Icahn Enterprises G.P. Inc. (Icahn Enterprises GP), Beckton Corp. (Beckton) and Carl C. Icahn on October 30, 2019. According to this Schedule 13D/A, High River has (i) sole power to vote 7,045,949 Common Shares, (ii) shared power to vote 0 Common Shares, (iii) sole power to dispose of 7,045,949 Common Shares, and (iv) shared power to dispose of 0 Common Shares; Hopper has (i) sole power to vote 0 Common Shares, (ii) shared power to vote 7,045,949 Common Shares, (iii) sole power to dispose of 0 Common Shares, and (iv) shared power to dispose of 7,045,949 Common Shares; Barberry has (i) sole power to vote 0 Common Shares, (ii) shared power to vote 7,045,949 Common Shares, (iii) sole power to dispose of 0 Common Shares, and (iv) shared power to dispose of 7,045,949 Common Shares; Icahn Partners Master Fund has (i) sole power to vote 11,469,454 Common Shares, (ii) shared power to vote 0 Common Shares, (iii) sole power to dispose of 11,469,454 Common Shares, and (iv) shared power to dispose of 0 Common Shares; Icahn Offshore has (i) sole power to vote 0 Common Shares, (ii) shared power to vote 11,469,454 Common Shares, (iii) sole power to dispose of 0 Common Shares, and (iv) shared power to dispose of 11,469,454 Common Shares; Icahn Partners has (i) sole power to vote 16,712,501 Common Shares, (ii) shared power to vote 0 Common Shares, (iii) sole power to dispose of 16,712,501 Common Shares, and (iv) shared power to dispose of 0 Common Shares; Icahn Onshore has (i) sole power to vote 0 Common Shares, (ii) shared power to vote 16,712,501 Common Shares, (iii) sole power to dispose of 0 Common Shares, and (iv) shared power to dispose of 16,712,501 Common Shares; Icahn Capital has (i) sole power to vote 0 Common Shares, (ii) shared power to vote 28,181,955 Common Shares; (iii) sole power to dispose of 0 Common Shares, and (iv) shared power to dispose of 28,181,955 Common Shares; IPH has (i) sole power to vote 0 Common Shares, (ii) shared power to vote 28,181,955 Common Shares, (iii) sole power to dispose of 0 Common Shares, and (iv) shared power to dispose of 28,181,955 Common Shares; Icahn Enterprises Holdings has (i) sole power to vote 0 Common Shares, (ii) shared power to vote 28,181,955 Common Shares, (iii) sole power to dispose of 0 Common Shares, and (iv) shared power to dispose of 28,181,955 Common Shares; Icahn Enterprises GP has (i) sole power to vote 0 Common Shares, (ii) shared power to vote 28,181,955 Common Shares, (iii) sole power to dispose of 0 Common Shares, and (iv) shared power to dispose of 28,181,955 Common Shares; Beckton has (i) sole power to vote 0 Common Shares, (ii) shared power to vote 28,181,955 Common Shares, (iii) sole power to dispose of 0 Common Shares, and (iv) shared power to dispose of 28,181,955 Common Shares; and Carl C. Icahn has (i) sole power to vote 0 Common Shares, (ii) shared power to vote 35,227,904 Common Shares, (iii) sole power to dispose of 0 Common Shares, and (iv) shared power to dispose of 35,227,904 Common Shares. The address for (i) each of High River, Hopper, Barberry, Icahn Master, Icahn Offshore, Icahn Partners, Icahn Onshore, Icahn Capital, IPH, Icahn Enterprises Holdings, Icahn Enterprises GP and Beckton is White Plains Plaza, 445 Hamilton Avenue Suite 1210, White Plains, NY 10601, and (ii) Mr. Icahn is c/o Icahn Associates Corp., 767 Fifth Avenue, 47th Floor, New York, NY 10153. |
60 | Security ownership of certain beneficial owners and management |
(13) | The information regarding the beneficial ownership of Deccan Value Investors L.P. is based on the Schedule 13G filed jointly with the SEC by Deccan Value Investors L.P. and Vinit Bodas on February 14, 2020. According to this Schedule 13G, each reporting person has (i) sole power to vote 0 Common Shares, (ii) shared power to vote 10,429,442 Common Shares, (iii) sole power to dispose of 0 Common Shares and (iv) shared power to dispose of 10,429,442 Common Shares. The address for each reporting person is One Fawcett Place, Greenwich CT 06830. |
(14) | The information regarding the beneficial ownership of The Vanguard Group 23-1945930 (the Vanguard Group) is based on the Schedule 13G/A filed with the SEC by the Vanguard Group on February 12, 2020. According to this Schedule 13G/A, the Vanguard Group has (i) sole power to vote 53,156 Common Shares, (ii) shared power to vote 17,738 Common Shares, (iii) sole power to dispose of 9,606,229 Common Shares, (iv) shared power to dispose of 57,446 Common Shares. The address for the Vanguard Group is 100 Vanguard Blvd., Malvern, PA 19355. |
(15) | The information regarding the beneficial ownership of Renaissance Technologies LLC is based on the Schedule 13G/A filed jointly with the SEC by Renaissance Technologies LLC and Renaissance Technologies Holdings Corporation on February 13, 2020. According to this Schedule 13G/A, the reporting persons each have (i) sole power to vote 8,561,703 Common Shares, (ii) shared power to vote 0 Common Shares, (iii) sole power to dispose of 8,561,703 Common Shares and (iv) shared power to dispose of 0 Common Shares; Renaissance Technologies Holdings Corporations beneficial ownership results from its majority ownership of Renaissance Technologies LLC. The address for the reporting persons is 800 Third Avenue, New York, New York 10022. |
(16) | HBL Swiss Services GmbH (formerly known as HBL Swiss Financing GmbH) has (i) sole power to vote 10,025,020 Common Shares, (ii) shared power to vote 0 Common Shares, (iii) sole power to dispose of 10,025,020 Common Shares and (iv) shared power to dispose of 0 Common Shares. The address for HBL Swiss Services GmbH is Hansmatt 32, CH-6370 Stans NW, Switzerland. |
(17) | Number of outstanding Common Shares used to calculate percentage excludes Common Shares held by HBL Swiss Services GmbH, the Companys indirect wholly-owned subsidiary, in accordance with Instruction 1 to Item 403 of Regulation S-K. If the Common Shares held by HBL Swiss Services GmbH are included in the total number of Common Shares outstanding as of March 2, 2020, or 147,701,213, its percentage ownership would be 6.79%. |
Security ownership of certain beneficial owners and management | 61 |
Part 7
|
Additional information |
Information with respect to securities authorized for issuance under equity compensation plans
The following table sets forth as of December 31, 2019, information with respect to (a) the number of securities to be issued upon exercise of outstanding options, warrants, and rights, (b) the weighted-average exercise price of outstanding options, warrants, and rights and (c) the number of securities remaining available for future issuance under equity compensation plans.
Number of Securities |
Weighted-Average |
Number of
Securities
|
||||||||||
|
(a) |
(b) |
(c) |
|||||||||
Equity compensation plans approved by security holders(1) |
5,030,773 | $27.85 | 8,898,862 | |||||||||
Equity compensation plans not approved by security holders |
| | | |||||||||
Total |
5,030,773 | $27.85 | 8,898,862 |
(1) | Consists of the Amended and Restated Herbalife Ltd. 2005 Stock Incentive Plan and the Amended and Restated Herbalife Ltd. 2014 Stock Incentive Plan. In February 2008, a shareholder-approved Employee Stock Purchase Plan was implemented. See note 9 of the notes to consolidated financial statements included in the Companys Annual Report on Form 10-K for the year ended December 31, 2019 regarding share-based compensation. |
(2) | Includes 3.2 million common shares available for future issuance under the shareholder approved Employee Stock Purchase Plan which was implemented in February 2008. |
(3) | Number of securities to be issued upon exercise of SARs was calculated using the market price as of December 31, 2019. |
Householding of proxy materials
64 | Additional information |
|
PRELIMINARY PROXY CARD SUBJECT TO COMPLETION DATED MARCH 5, 2020
PRELIMINARY PROXY CARD- SUBJECT TO COMPLETION DATED MARCH 5, 2020C123456789 000000000.000000 ext 000000000.000000 ext 000004 000000000.000000 ext 000000000.000000 ext ENDORSEMENT_LINE______________ SACKPACK_____________ 000000000.000000 ext 000000000.000000 ext Your vote matters heres how to vote! MR A SAMPLE You may vote online or by phone instead of mailing this card. DESIGNATION (IF ANY) Votes submitted electronically must be ADD 1 ADD 2 received by 11:59 p.m., Eastern Time on ADD 3 April 28, 2020. ADD 4 ADD 5 Online ADD 6 Go to www.envisionreports.com/HLF or scan the QR code login details are located in the shaded bar below. Phone Call toll free 1-800-652-VOTE (8683) within the USA, US territories and Canada Save paper, time and money! Using a black ink pen, mark your votes with an X as shown in this example. Sign up for electronic delivery at Please do not write outside the designated areas. www.envisionreports.com/HLF 2020 Annual Meeting Proxy Card 1234 5678 9012 345 qIF VOTING BY MAIL, SIGN, DETACH AND RETURN THE BOTTOM PORTION IN THE ENCLOSED ENVELOPE. q A Proposals The Board of Directors recommend a vote FOR each nominee listed below and FOR Proposals 2 through 5. 1. Election of Directors: For Against Abstain For Against Abstain For Against Abstain + 01John Agwunobi 02James L. Nelson 03Richard H. Carmona 04Jonathan Christodoro 05Hunter C. Gary 06Nicholas Graziano 07Alan LeFevre 08Jesse A. Lynn 09Juan Miguel Mendoza 12Margarita Paláu- 10Michael Montelongo 11Maria Otero Hernández 13John Tartol For Against Abstain For Against Abstain 2. Approve, on an advisory basis, the compensation of the Companys named 3. Approve, as a special resolution, an amendment to the executive officers. Companys Amended and Restated Memorandum and Articles of Association to eliminate the casting vote. 4. Approve, as a special resolution, an amendment to the Companys Amended 5. Ratify the appointment of the Companys and Restated Memorandum and Articles of Association to require the independent registered public accounting firm for approval of two-thirds of the members of the Board of Directors then in office fiscal year 2020. to amend the Companys Principles of Corporate Governance to make any changes to the responsibilities of the Chairman of the Board or the Lead Director as set forth therein. B Authorized Signatures This section must be completed for your vote to count. Please date and sign below. Please sign exactly as name(s) appears hereon. Joint owners should each sign. When signing as attorney, executor, administrator, corporate officer, trustee, guardian, or custodian, please give full title. Date (mm/dd/yyyy) Please print date below. Signature 1 Please keep signature within the box. Signature 2 Please keep signature within the box. C 1234567890J N T MR A SAMPLE (THIS AREA IS SET UP TO ACCOMMODATE 140 CHARACTERS) MR A SAMPLE AND MR A SAMPLE AND MR A SAMPLE AND MR A SAMPLE AND MR A SAMPLE AND MMMMMM 1UPX 450062 MR A SAMPLE AND MR A SAMPLE AND MR A SAMPLE AND + 037MAA inproposal1
Important notice regarding the Internet availability of proxy materials for the Annual General Meeting of Shareholders. The material is available at: www.envisionreports.com/HLF Small steps make an impact. Help the environment by consenting to receive electronic delivery, sign up at www.envisionreports.com/HLF qIF VOTING BY MAIL, SIGN, DETACH AND RETURN THE BOTTOM PORTION IN THE ENCLOSED ENVELOPE. q ProxyHerbalife Nutrition Ltd. + Notice of 2020 Annual General Meeting of Shareholders Proxy Solicited by Board of Directors for Annual General Meeting of Shareholders April 29, 2020 John Agwunobi and Henry Wang, or any of them, each with the power of substitution, are hereby authorized to represent and vote the shares of the undersigned, with all the powers which the undersigned would possess if personally present, at the Annual General Meeting of Shareholders of Herbalife Nutrition Ltd. to be held on April 29, 2020 at 8:30 a.m., Pacific Daylight Time, at 800 W. Olympic Blvd., Suite 406, Los Angeles, CA 90015 or at any postponement or adjournment thereof. Shares represented by this proxy will be voted by the shareholder. If no such directions are indicated, the Proxies will have authority to vote FOR the election of the Board of Directors and FOR items 2 through 5. In their discretion, the Proxies are authorized to vote upon such other business as may properly come before the meeting. (Items to be voted appear on reverse side) C Non-Voting Items Change of Address Please print new address below. Comments Please print your comments below. + each Proposals each nominee listed inProposal1